Pain is a subjective response with multiple features and components, said Frank Porreca, PhD, professor of pharmacology and anesthesiology at the University of Arizona and a member of the Department of Collaborative Research at Mayo Clinic in Arizona.
Pain is a subjective response with multiple features and components, said Frank Porreca, PhD, professor of pharmacology and anesthesiology at the University of Arizona and a member of the Department of Collaborative Research at Mayo Clinic in Arizona.
Transcript:
The American Journal of Managed Care® (AJMC®): Can you elaborate on your research into understanding pain-induced motivational behavior and reward circuits as a basis for discovering new migraine therapies with a high likelihood of translation?
Dr. Porreca: One of the problems that we've always had is to measure pain. Pain is a subjective response, and so it has multiple components. It has a sensory component. We can sort of know where the pain is, we can discriminate the location of the pain: it's in my finger, it's in my shoulder, whatever it is. But it also has other features that are a little bit different from other sensory responses. Pain has an affective component and a motivational component. So pain is a sensation, but unlike other sensations that are sort of affectively neutral, pain is unpleasant. Pain is always unpleasant. It's unpleasant at threshold. It's the unpleasantness of pain that produces motivation. We have pain, we have strong motivation to escape and to seek relief from that pain condition.
The reason for describing that, is how do we measure pain? Well, measuring pain, even in humans is difficult. The way that we measure pain in humans is we ask humans about their pain. We say, 'how much pain do you have?' We use rating scales, numerical rating scales, visual analog scales, something like that, and the humans tell us. Now it's okay to do that and we believe humans when they tell us their pain is an 8 out of 10, or 7 out of 10, or 5 out of 10. But what we would prefer to do is we'd like to have an objective measure of pain, sort of like a blood test. What is your cholesterol level, you know? You get a number. We don't have that in humans, because pain, again, is fundamentally subjective.
Now, if you take that, and you translate it to the preclinical laboratory, and you say, how do we measure pain in a non-verbal animal? Well, that becomes particularly challenging, because we can't ask the animal about their pain, and yet, we'd like to know if our treatment produced relief of pain, like in migraine. So one of the things that we have done is we focused on the motivational qualities of pain. Pain is aversive, it produces motivation to escape and to seek relief. What we find is that if we have relief of an aversive state, then that is actually rewarding. The way that you can think about it is if it's a very, very hot day, for example, and you jump in the swimming pool, well, that makes you feel better. Relief of an aversive state is rewarding, and it activates the classical mesolimbic dopaminergic reward pathway. And it produces motivation. That's what we've done. If we have ongoing pain, we produce relief of ongoing pain that animals will seek; a context that there is a learning paradigm where they can seek a context that's associated with relief of that aversive state. That gives us insight into whether the pain is there and secondly, whether the treatment that we've given, is effective in producing relief of pain by removing the motivation on the part of the animal to seek a context that's associated with with relief of an aversive state.
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More